Literature DB >> 16808130

Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin.

Edward V Barnes1, David P Dooley, Matthew J Hepburn, Sue E Baum.   

Abstract

Community-acquired, methicillin-resistant Staphylococcus aureus (cMRSA), soft tissue infections are becoming increasingly prevalent in the outpatient setting. Few studies have been specifically designed to examine the efficacy of oral antibiotic therapy for these infections. We performed an observational study to determine the effect of alternative, orally administered antibiotics on cMRSA soft tissue infections. Consecutive patients between January 2001 and March 2004 who had skin or soft tissue infections from which cMRSA was isolated and who had never received vancomycin were studied through retrospective and concurrent review. Primary outcome measures were improvement or resolution of infection 5 and 14 days after initiation of treatment with orally administered antibiotics and rates of recurrence within 30 days after completion of treatment. Thirty subjects met the inclusion criteria. Twenty-one subjects received either clindamycin, trimethoprim/sulfamethoxazole, doxycycline/minocycline, or a fluoroquinolone. Five subjects received a beta-lactam antibiotic with abscess drainage, and four subjects underwent abscess drainage alone. Improvement was noted for all subjects at 5 days, complete resolution of infection occurred for all subjects by 14 to 17 days, and in no case did relapse occur within 30 days. cMRSA skin and soft tissue infections can be successfully treated with orally administered antibiotics to which the organism has demonstrable in vitro susceptibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808130     DOI: 10.7205/milmed.171.6.504

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  8 in total

1.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

2.  Treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Kyle J Popovich; Bala Hota; Robert A Weinstein
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

3.  Treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Kyle J Popovich; Bala Hota; Robert A Weinstein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

4.  Skin and soft-tissue infections in suburban primary care: epidemiology of methicillin-resistant Staphylococcus aureus and observations on abscess management.

Authors:  Charles Weiss; Peggy Kaminsky; John Boggs; Catherine Ley
Journal:  BMC Res Notes       Date:  2011-02-07

Review 5.  Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin.

Authors:  Christian Eckmann; M Dryden
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

6.  Oral Antimicrobial Therapy: Efficacy and Safety for Methicillin-Resistant Staphylococcus aureus Infections and Its Impact on the Length of Hospital Stay.

Authors:  Young Kyung Yoon; Eu Suk Kim; Jian Hur; Shinwon Lee; Shin Woo Kim; Jin Won Cheong; Eun Ju Choo; Hong Bin Kim
Journal:  Infect Chemother       Date:  2014-09-24

Review 7.  Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review.

Authors:  Nicholas W Carris; Joe Pardo; Jose Montero; Kristy M Shaeer
Journal:  Open Forum Infect Dis       Date:  2015-11-25       Impact factor: 3.835

Review 8.  Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.

Authors:  Monique R Bidell; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2021-10-05       Impact factor: 6.251

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.